Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Cancer specialists outline new IMRT cancer treatments

Varian : 31 October, 2007  (New Product)
Two noted cancer treatment specialists have reported how they are using Varian Medical Systems’ technologies to more accurately target tumours and speed up delivery of ultra-precise intensity-modulated radiotherapy (IMRT) treatments.
An expert from the BC Cancer Agency in British Columbia presented an approach to volumetric arc radiotherapy, which makes it possible to deliver an IMRT treatment up to eight times faster than is possible with conventional treatment approaches.

An expert from Stanford University has also outlined novel image-guided motion management techniques for accurately treating lung cancer and other tumours that move during treatment as the patient breathes.

The presentations were part of an Emerging Technologies Symposium sponsored by Varian in connection with the annual meeting here of the American Society for Therapeutic Radiology and Oncology (ASTRO).

W James Morris, MD, associate professor at the University of British Columbia and radiation oncologist with the BC Cancer Agency, presented an approach to volumetric arc therapy (VMAT) that has been developed and used at his agency to deliver an ultra-precise IMRT treatment for prostate cancer in less than two minutes. This type of treatment normally would take at least ten minutes to deliver. A VMAT treatment is faster because it delivers a full dose to the entire targeted tumour volume with just a single rotation of the treatment machine around the patient.

'The treatments are delivered with high levels of dosimetric accuracy,' Morris said. 'The dose distributions with VMAT are equal or better to the ones you can get using conventional IMRT delivery techniques, and much faster to deliver.'

Billy W Loo, Jr, MD, PhD of Stanford University, Palo Alto, California, USA, described how his team uses 4D CT scans, which are images that correspond with particular phases of the patient's respiratory cycle, to create a respiratory gating strategy for triggering the treatment beam on and off in timed bursts that are synchronized with the patient's breathing.

Prior to each treatment, Loo's team verifies that the programmed respiratory gating strategy is still valid by studying fluoroscopic (moving) and cone-beam CT (volumetric) images of the targeted area and surrounding anatomy, generated using Varian's On-Board Imager device.

'Near-real-time image guidance tools are the wave of the future, because they will enable us to be much more accurate in how we address motion and reduce treatment margins to spare more healthy tissue,' Loo said.

Varian CEO Tim Guertin introduced Varian's new RapidArc radiotherapy, the company's new VMAT technology that will enable clinicians to deliver highly-conformal treatments much faster than is possible with conventional or helical IMRT (tomotherapy). Guertin said that Varian's goal is: 'to reduce the amount of time it takes to deliver these treatments - the best available - to less than five minutes. Two minutes to set the patient up for treatment, and two to treat - that's where we're headed,' he said.

'Faster imaging and faster treatment, with no sacrifice in terms of accuracy or precision, are going to be the cornerstones of effective, affordable cancer care.'

RapidArc is pending FDA 510(k) clearance, and not yet available for sale in the USA.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo